Ironwood, Forest Labs, Corden extend commercial supply agreement

Ironwood Pharmaceuticals (IRWD) disclosed in a regulatory filing that on November 26 the company, Forest Laboratories (FRX) and Corden Pharma Colorado amended their commercial supply agreement related to the manufacture and supply of linaclotide active pharmaceutical ingredient for North America. The amendment, among other things, extends the initial term of the agreement by four years to March 31, 2020. Ironwood and Forest are parties to a collaboration agreement, dated as of September 12, 2007, for the development and commercialization of linaclotide in North America. Under the terms of the collaboration agreement, Forest is responsible, among other things, for drug product and finished goods manufacturing for its territory, and distributing the finished goods to wholesalers.

View Comments (0)